Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.57 |
| ▸ | CDK9 | P50750 | 9/20 | 0.57 |
| ▸ | AURKA | O14965 | 7/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.57 |
| ▸ | CDK4 | P11802 | 6/20 | 0.57 |
| ▸ | CDK1 | P06493 | 5/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 5/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
| ▸ | CCNH | P51946 | 2/20 | 0.52 |
| ▸ | WEE1 | P30291 | 5/20 | 0.51 |
| ▸ | FLT3 | P36888 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.51 |
| ▸ | PAK4 | O96013 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073904 | 0.92 | CDK2 (0.57) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL2075857 | 0.90 | CDK2 (0.56) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL12841836 | 0.86 | CDK2 (0.55) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL2076824 | 0.86 | CDK2 (0.57) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL1704253 | 0.85 | CDK2 (0.53) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL12842041 | 0.85 | CDK2 (0.58) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL2073788 | 0.84 | CDK2 (0.62) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL27624139 | 0.84 | CDK2 (0.52) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL2074184 | 0.83 | CDK2 (0.63) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL2075354 | 0.83 | CDK2 (0.70) | CDK2CDK9AURKAAURKBCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | claimed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | claimed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | CDK2 1/4885CDK9 5/4885AURKA 123/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | CDK2 1/4885CDK9 5/4885AURKA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.